Publications by authors named "Anthony Marketon"
Article Synopsis
- - Lassa virus (LASV) leads to hundreds of thousands of infections in Western Africa annually, with about 20% progressing to Lassa fever, a serious disease that has a high fatality rate.
- - Currently, there are no approved vaccines or treatments for Lassa fever, but researchers have been working on recombinant LASVs (rLASVs) that show promising results as vaccines in animal models.
- - The new vaccine candidate, rLASV/IGR-CD, demonstrated high safety and effectiveness in guinea pigs, offering complete protection against lethal LASV exposure and advancing the development of a live-attenuated vaccine for Lassa fever.
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and onset of the coronavirus disease-19 (COVID-19) pandemic led to an immediate need for therapeutic treatment options. Therapeutic antibodies were developed to fill a gap when traditional antivirals were not available. In late 2020, the United States Government undertook an effort to compare candidate therapeutic antibodies in virus neutralization assays and in the hamster model of SARS-CoV-2 infection.
View Article and Find Full Text PDFAllergies caused by Japanese Red Cedar (JRC) pollen affect up to a third of Japanese people, necessitating development of an effective therapeutic. We utilized the lysosomal targeting property of lysosomal-associated membrane protein-1 (LAMP-1) to make DNA vaccines that encode LAMP-1 and the sequences of immunodominant allergen CryJ1 or CryJ2 from the JRC pollen. This novel strategy is designed to skew the CD4 T cell responses to the target allergens towards a nonallergenic Th1 response.
View Article and Find Full Text PDF